Pancreatic cancer check (a) of the preferred laboratory abnormalities
Tumor marker for pancreatic cancer more than ten species, but the early diagnosis of pancreatic cancer of little value, the positive rate low, but specificity is not strong, it is that pancreatic cancer is mainly used to determine whether there is residual disease after resection, and recurrence of monitoring. Current clinical application of more markers for the CAI9-9, normal: <37/ml; CCA, normal: <10g / L, reported screening for high risk groups to CA19-9 is superior to CCA, cancer to normal after excision, recurrence Shiyou increased. Other still Dupan-2, pancreatic cancer antigen (POA), pancreas-specific antigen (PSA) and so on. Pancreatic cancer detection: detection is commonly used in patients with pancreatic juice in the K-r gene mutation, but the false positive rate is higher. Recent national reports to improve DNA extraction method for detection of fecal stool K-ras gene mutation in the mutation rate of 88% but benign tumor of the pancreas and the control group had a certain mutation rate.
Pancreatic cancer check (b) of the preferred non-invasive imaging
The most commonly used B-abdominal pancreatic tumor images of typical B-hypoechoic, heterogeneous mass of irregular edges, a pseudopod-like extension; another, such as pancreatic head diameter greater than 4cm, offenders are usually prompt with pancreatic head lesions. Followed by abdominal CT should be enhanced helical CT, showed low-density mass, pancreas and pancreas often extend outside the shadow outline of the pancreas surrounding fat layer disappears. Magnetic resonance cholangiopancreatography (MRCP), its performance for the proximal pancreatic duct dilatation. Currently have on the application of positron emission tomography (PCT) to diagnose pancreatic cancer. Invasive imaging with endoscopic ultrasonography, retrograde cholangiopancreatography (CRCP), abdominal blood vessel selective angiography, percutaneous transhepatic angiography (PrC) (only for clinical disease who have obstructive yellow) and so on. Comparison of various imaging diagnosis: 100% endoscopic ultrasonography, abdominal B-29%, CRCP89%, CT81%. Early cancer is less than 2cm in diameter: 100% EUS, abdominal B-29%, CT29%, CRCP57% (the comparison by the diagnosis in 52 cases of pancreatic cancer derived). Of the general population and high-risk screening population monitoring, mainly abdominal B-, followed by CT; on clinical symptoms, or suspected pancreatic cancer, the check is in order: abdominal B- CT MRCP endoscopic ultrasound. Of the CRCP, angiography, and PrC, as the case may be.